Abstract: The incidence of triple-negative breast cancer (TNBC) is approximately 10-15% of all breast cancer cases around the world. It is important to search for novel therapeutic agents against TNBC since this form of cancer is a leading cause of death in women worldwide. Various genetic mutations in TNBC patients have been identified. EZH2 is an oncoprotein involved in breast, prostate, colon, and other cancers. In silico drug design and bioinformatics studies.....
Keywords : Triple Negative Breast Cancer, Drug Repurposing, Epithelial Mesenchymal Transition, Molecular Docking.
[1]
Huang, Jinhua, Gou, Hongwei, Yao, Jia, Yi, Kaining, Jin, Zhigang, Matsuoka, Masao, & Zhao, Tiejun (2021). The Noncanonical Role Of EZH2 In Cancer. Cancer Science, 112(4), 1376-1382. Https://Onlinelibrary.Wiley.Com/Doi/Full/10.1111/Cas.14840
[2]
“Leading Causes Of Death.” Centers For Disease Control And Prevention, 6 February 2020,
Https://Www.Cdc.Gov/Nchs/Fastats/Leading-Causes-Of-Death.Html. Accessed 30 September 2020
[3]
Noer, Julie B., Hørsdal, Oskar K., Xiang, Xi, Luo, Yonglun, Regenberg, Birgitte, "Extrachromosomal Circular DNA In Cancer: History, Current Knowledge, And Methods." Trends In Genetics (2022).
Https://Www.Sciencedirect.Com/Science/Article/Pii/S0168952522000348
[4]
Patel, Shivali, Charles V. Preuss, And Fidelia Bernice. "Vancomycin." Statpearls [Internet]. Statpearls Publishing, 2022.
Https://Www.Ncbi.Nlm.Nih.Gov/Books/NBK459263/
[5]
Samaržija I, Tomljanović M, Novak Kujundžić R, Trošelj KG. EZH2 Inhibition And Cisplatin As A Combination Anticancer Therapy: An Overview Of Preclinical Studies. Cancers (Basel). 2022 Sep 29;14(19):4761. Doi: 10.3390/Cancers14194761 . PMID: 36230683; PMCID: PMC9561994..